Complete clearance lasts for a very long time due to knockout of resident memory T cells within the skin,’ said the study’s ...

Johnson & Johnson JNJ announced that the European Commission (EC) has approved an expanded use of its blockbuster psoriasis ...

Today, Takeda announced positive topline results from 2 pivotal phase 3 trials of zasocitinib (TAK-279; Takeda), demonstrating superiority over placebo across key efficacy end points in adults with ...

Over 8 million adults in the U.S. experience plaque psoriasis — a chronic autoimmune disease that causes painful, raised, scaly spots on the skin. People with plaque psoriasis often employ a host of ...

Oral roflumilast showed potential as a nonbiologic systemic therapy for moderate to severe psoriasis, offering an alternative ...

The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to ...

Compared to Sotyktu (deucravacitinib), which was approved by the FDA for plaque psoriasis in 2022 and brought in sales of ...

Japan's Takeda Pharmaceutical said on Thursday its experimental pill for a type of skin disease, developed using artificial ...

A real-world analysis reveals that tildrakizumab is highly effective and safe in patients with moderate-to-severe plaque ...

In a combined network meta-analysis, infliximab and adalimumab had the greatest risk for serious infection in patients with plaque psoriasis.

Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...

—A growing body of evidence has revealed several comorbidities associated with generalized plaque psoriasis. A new study takes a closer look at possible shared risks for a subtype, palmoplantar ...